Physician profile
Thomas Durick
NPI 1194794628
$42,980.18
in general payments reported to CMS, 2019-2025
6 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,410 · 2022: $145 · 2024: $8,764 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Travel and Lodging: $5,528 · Long Term Medical Supply Or Device Loan: $3,899 · Food and Beverage: $658 · Consulting Fee: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,875.00 |
| Travel and Lodging | $5,528.16 |
| Long Term Medical Supply Or Device Loan | $3,899.00 |
| Food and Beverage | $658.00 |
| Consulting Fee | $465.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $29,857.51 | 2024-2025 | Fisher & Paykel Healthcare |
| Arthrex, INC. | $8,410.04 | 2019 | |
| Butterfly Network, INC. | $4,364.00 | 2024-2025 | |
| Pacira Pharmaceuticals Incorporated | $203.65 | 2025 | Iovera |
| Acacia Pharma INC | $77.25 | 2022 | |
| Fresenius Kabi USA, LLC | $67.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Durick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.